Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation by Hui Ma, Zhongchen Li, Jia Yuan, Lan Zhang, Xiaoying Xie, Xin Yin, Rongxin Chen, Zhenggang Ren

“…Recurrence after curative resection for hepatocellular carcinoma (HCC) is a major cause of death from this disease. …”
Get full text

The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells by Minghao Sui, Tiantian Liu, Xuanli Song, Ji Li, Han Ding, Yuqian Liu, Xinyu Wang, Huimin Liu, Yuchan Xue, Jianni Qi, Miao Zhang, Songbo Zhao, Qiang Zhu

Subjects: Get full text

Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation by Francesco Fiorica, Carlo Greco, Sergio Boccia, Sergio Sartori, Antonio Stefanelli, Francesco Cartei, Stefano Ursino

“…Transarterial chemoembolization is the first-line treatment in unresectable hepatocellular carcinoma. There is no standard treatment after transarterial chemoembolization failure. …”
Get full text

Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications by David A. Close, Paul A. Johnston

Subjects: “…Hepatocellular carcinoma organoids…”
Get full text

H. Wendl Leaf Metabolites Potentiate the Radiosensitivity of Hepatocellular Carcinoma Through Ki67 and PARP Inhibition by Nabil M. Selim PhD, Seham S. El-Hawary PhD, Soheir M. El Zalabani PhD, Rehab Nabil Shamma PhD, Nariman El Sayed Mahdy PhD, Noheir H. Sherif PhD, Khayrya A. Youssif PhD, Usama Ramadan Abdelmohsen PhD, Mai H. Mekkawy PhD, Hanan A. Fahmy PhD

“…Objectives: Hepatocellular carcinoma (HCC) represents the third-most prevalent cancer in humans worldwide. …”
Get full text

Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival by Jared R. Robbins, Ryan K. Schmid, Abdulrahman Y. Hammad, Thomas Clark Gamblin, Beth A. Erickson

Subjects: “…hepatocellular carcinoma…”
Get full text

Retracted: Clinical Value of PPM1G Gene in Survival Prognosis and Immune Infiltration of Hepatocellular Carcinoma by Applied Bionics and Biomechanics

Get full text

Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo by Song He, Ying-ze Wei, Gui-lan Wang, Yu-yin Xu, Jia-ming Zhou, Yi-xin Zhang, Li Chen

Get full text

The miRNA‐mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO by Razieh Heidari, Vahideh Assadollahi, Seyedeh Negar Marashi, Fatemeh Elahian, Seyed Abbas Mirzaei

Subjects: Get full text

Serum chemerin level in patients with liver cirrhosis and primary and multifocal hepatocellular carcinoma with consideration of insulin level by Monika Pazgan-Simon, Anna Szymanek-Pasternal, Joanna Górka-Dynysiewicz, Anna Nowicka, Krzysztof Simon, Ewa Grzebyk, Michał Kukla

Subjects: Get full text

Shotgun Metagenomics Reveals Bacteroides stercoris as a Fecal Biomarker Depleted in Late-Stage Hepatocellular Carcinoma by Damien Esparteiro, Grégory Fouquet, Anoïsia Courtois, Mickaël Naassila, Eric Nguyen-Khac, Ingrid Marcq

Get full text

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment by Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan

“…Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.…”
Get full text

Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma by Maiweilidan Yimingjiang, Talaiti Tuergan, Xinhua Chen, Hao Wen, Yingmei Shao, RuiQing Zhang, Kasimu Aihaiti, Jing Xue, Tuerganaili Aji, Wei Zhang

“…Nanosecond pulsed electric field (NsPEF) ablation effectively eliminates early-stage hepatocellular carcinoma (HCC) by local ablation and advanced HCC by inducing a remarkable and sustained host immune response. …”
Get full text

Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN by Yuan Zeng, Haoran Jiang, Zhoufeng Chen, Jun Xu, Xiangting Zhang, Weimin Cai, Xianjie Zeng, Peipei Ma, Rong lin, Huilin Yu, Yuanhang He, Huiya Ying, Ruoru Zhou, Xiao Wu, Fujun Yu

“…Abstract FOLFOX (5-fluorouracil, oxaliplatin, folinic acid) is a standard treatment for hepatocellular carcinoma, but its efficacy is often limited by drug resistance, the underlying mechanisms of which remain unclear. …”
Get full text

miR-559 Inhibits Proliferation, Autophagy, and Angiogenesis of Hepatocellular Carcinoma Cells by Targeting PARD3 by Chunjing Wang, Chengcheng Li, Rui Hao

“…Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and has a high mortality rate. …”
Get full text

Quantification of Pregenomic RNA and Covalently Closed Circular DNA in Hepatitis B Virus-Related Hepatocellular Carcinoma by Fugui Bai, Yoshihiko Yano, Takumi Fukumoto, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Nungki Anggorowati, Hanggoro Tri Rinonce, Dewiyani Indah Widasari, Masaya Saito, Hirotaka Hirano, Takanobu Hayakumo, Yasushi Seo, Takeshi Azuma, Yonson Ku, Yoshitake Hayashi

“…Thirty-eight hepatocellular carcinoma (HCC) patients, including 14 positive for hepatitis B surface antigen (HBsAg) and 24 negative for HBsAg but positive for anti-hepatitis B core (anti-HBc) antibody, were enrolled in this study. …”
Get full text

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma by Yonghua Bi, Dechao Jiao, Jianzhuang Ren, Xinwei Han

“…Although raltitrexed shows therapeutic effects in many types of malignant tumors, the therapeutic effects and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) loaded with raltitrexed for the treatment of hepatocellular carcinoma (HCC) are rare. This study aimed to investigate the safety and efficacy of DEB-TACE with raltitrexed-loaded CalliSpheres beads (CB) in patients with unresectable or recurrent HCC. …”
Get full text

Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma by Hanchuan Tao, Cheng Wang, Chongmei Lu, Ning Ma, Yifan Zhu, Shihai Xuan, Xiaojun Zhou

“…Background. Liver hepatocellular carcinoma (LIHC) is the predominant type of liver cancer, and its treatment still faces great challenges presently. …”
Get full text

(−)-Epigallocatechin-3-Gallate and Quercetin Inhibit Quiescin Sulfhydryl Oxidase 1 Secretion from Hepatocellular Carcinoma Cells by Lumin Yang, Yuying Fang, Yufeng He, Jinsong Zhang

Subjects: Get full text

Identification of Hepatocellular Carcinoma Subtypes Based on Global Gene Expression Profiling to Predict the Prognosis and Potential Therapeutic Drugs by Cunzhen Zhang, Jiyao Wang, Lin Jia, Qiang Wen, Na Gao, Hailing Qiao

Subjects: “…hepatocellular carcinoma…”
Get full text